Figure 1
Figure 1. BLyS expression by mDCs. (A) Cells were gated on total live PBMC and then on CD3−HLA-DR+ cells (mDCs; left panel). MDCs are CD11c+CD14−CD16− or CD11c+CD14−CD16+ (middle and right panels). (B) Membrane BLyS expression in CD16− mDCs of rapid progressors (left panel), normal progressors (middle panel), and slow progressors (right panel). (C) Membrane BLyS expression in CD16+ mDCs of rapid progressors (left panel), normal progressors (middle panel), and slow progressors (right panel). The same values are used for HIV-negative donors in the left, middle, and right graphs to show this group as a control. Membrane BLyS expression is defined as the calibrated geometric and compared with the Wilcoxon signed rank and Mann-Whitney U tests for pairwise comparisons of different phases of infection within each group and between the study groups, respectively. *P < .05. PI indicates postinfection; and ART, antiretroviral treatment.

BLyS expression by mDCs. (A) Cells were gated on total live PBMC and then on CD3−HLA-DR+ cells (mDCs; left panel). MDCs are CD11c+CD14−CD16− or CD11c+CD14−CD16+ (middle and right panels). (B) Membrane BLyS expression in CD16− mDCs of rapid progressors (left panel), normal progressors (middle panel), and slow progressors (right panel). (C) Membrane BLyS expression in CD16+ mDCs of rapid progressors (left panel), normal progressors (middle panel), and slow progressors (right panel). The same values are used for HIV-negative donors in the left, middle, and right graphs to show this group as a control. Membrane BLyS expression is defined as the calibrated geometric and compared with the Wilcoxon signed rank and Mann-Whitney U tests for pairwise comparisons of different phases of infection within each group and between the study groups, respectively. *P < .05. PI indicates postinfection; and ART, antiretroviral treatment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal